Genomics of myelodysplastic/myeloproliferative neoplasm | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Genomics of myelodysplastic/myeloproliferative neoplasm

Journal Title: 
Seminars in Diagnostic Pathology
Primary Author: 
Patwardhan PP
Patwardhan PP, Aarabi M, Aggarwal N
Original Publication Date: 
Wednesday, May 31, 2023
Bone Marrow Disease(s): 

Myelodysplastic/ Myeloproliferative neoplasms (MDS/MPN) demonstrate overlapping pathologic and molecular features of myelodysplastic (MDS) and myeloproliferative (MPN) neoplasms. Diagnosis is difficult based on morphology alone, requiring exclusion of various non-neoplastic causes for CBC abnormalities and morphologic findings and other myeloid neoplasms. Identifying a clonal abnormality by cytogenetics or molecular studies has vastly improved our ability to diagnose MDS/MPN and has been incorporated in the different classification schemas. Currently two separate classification systems are in use- The 5th edition WHO and international consensus classification. The two competing classifications emphasize genetic work-up and are similar on many levels; however, they do introduce diagnostic dilemma when diagnosing certain entities such as chronic myelomonocytic leukemia in the presence of NPM1 mutations. The genetic profile overlaps among different subentities; however, the combination and the incidence of mutations; together with the clinical features and morphology helps in further subclassification. In this review, we discuss the advances in molecular characterization of MDS/MPN. We attempt to summarize the differences between the various classification schemes, and highlight the changes made in the diagnostic criteria.